Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 17/20 | 0.50 |
| ▸ | CHUK | O15111 | 16/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544646 | 0.91 | IKBKB (0.48) | IKBKBCHUKSRC | |
| SCHEMBL2539360 | 0.91 | IKBKB (0.59) | IKBKBCHUK | |
| SCHEMBL2540573 | 0.86 | CDK1 (0.56) | IKBKB | |
| SCHEMBL2545770 | 0.85 | CAMK2D (0.51) | — | |
| SCHEMBL2544056 | 0.84 | GSK3B (0.54) | IKBKBCHUKERBB2PTK6 | |
| SCHEMBL2544634 | 0.83 | IKBKB (0.55) | IKBKBCHUK | |
| SCHEMBL2541859 | 0.80 | CDK2 (0.53) | — | |
| SCHEMBL2542401 | 0.79 | IKBKB (0.51) | IKBKBCHUKSRCERBB2PTK6 | |
| SCHEMBL2545759 | 0.79 | CDK1 (0.55) | IKBKB | |
| SCHEMBL2542388 | 0.79 | CAMK2D (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | claimed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | claimed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | claimed |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | MAP3K20, MAP3K1, MAP3K2 | IKBKB 348/4885CHUK 154/4885SRC 87/4885 |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | NFKBIA, IRAK1, IRAK3 | IKBKB 50/4885CHUK 31/4885SRC 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.